Engages in the development and commercialization of therapeutic products for underserved markets in the United States. Market cap at $1.1B.

4. Dendreon Corp. ( DNDN): Traded as high as $7, but fell to $5.67 recently. Maxim downgraded its shares, because the firm was concerned about sales of Provenge. Last year, shares were $17.50. Provenge is an expensive therapy, costing $93,000. Much of the trading in its shares is speculative: investors think the company could be taken over.

Engages in the discovery, development, and commercialization of therapeutics to enhance cancer treatment options for patients. Market cap at $845.67M.

( List compiled by Kapitall Contributor Chris Lau )


If you liked this article you might like

Biotech-Twitter 2014: A Look Back at the Biotech Year Through the Twitter Lens

Where Are They Now? A Look Back at the Best & Worst Biotech CEOs

Nominees for Absolute Worst Biotechnology CEOs of 2014 Are ...

Using Re-Engineered Immune Cells to Kill Leukemia Induces Lasting Remissions

Stock Market Today: S&P 500 Eyes Strong Finish for 2014; Alibaba Spikes